EVALUATION OF EFFICACY AND SAFETY OF RENOMET, A POLYHERBAL FORMULATION IN THE TREATMENT OF UROLITHIASIS: A DOUBLE BLIND RANDOMIZED STUDY
Abstract
Nephrolithiasis is one of the most commonly occurring disorders in India. Although this disorder is seen in any age group, young and middles aged individuals are the most common sufferers. The treatment of nephrolithiasis is mostly diuretics or surgical procedure. However, commonest complaint of patients where the stones have been removed surgically is recurrence. Therefore a need was felt to evaluate the efficacy of Renomet, a poly herbal product in the treatment of nephrolithiasis. Seventy four patients between 35-60 years of age and fulfilling inclusion criteria were included in the trial. All the patients had multiple stones up to 9 mm in size and had past history of renal stones surgically removed. They were divided in to two groups after obtaining the informed consent and administered either Renomet or a commercially available herbal formulation at the dose of 1 tablet twice daily for 6 weeks. Patients were asked to report for any side effect during the treatment period. At the end of the trial, patients in the Renomet treated group were found to be symptom free and about 98% of them had passed the stone. Where as in the herbal supplement (CAHP) group only 68% patients had passed stones. The average size of the stone in group A and B at the time of recruitment were 8.88 ± 0.26 and 7.10 ± 0.88 respectively. After 6 weeks of treatment with Renomet Group A), dysuria and hematuria improved in all (100%) and pain abdomen improved in 98.6% cases. In group B, after 6 weeks of treatment with CAHP, pain abdomen was still present in 8.7%, hematuria in 3.26% and dysuria in 14.99% of cases. The average size of the stone reduced to 4.1 ± 0.22 in group A, while in group B the size reduced to 5.56 ± 0.43.
Keywords:
Renomet, nephrolithiasis, calcium oxalate, Saxifraga lingulata, Tribulus terrestris, Dolichos biflorusDOI
https://doi.org/10.25004/IJPSDR.2012.040208References
2. Tiselius HG. Epidemiology and medical management of stone disease. BJU Int. 2003; 91: 758-767.
3. Devuyst O, Pirson Y. Genetics of hypercalciuric stone forming diseases. Kidney Int. 2007; 72: 1065-1072.
4. Knoll T. Stone disease. Eur Urol Suppl. 2007; 6: 717-722.
5. Worcester EM, Coe FL. Nephrolithiasis. Prim Care 2008; 35: 369-391.
6. Taylor EN, Stampfer MJ, Curhan GC. Obesity, weight gain, and the risk of kidney stones. JAMA 2005; 293: 455-462.
7. Obligado SH, Goldfarb DS. The association of nephrolithiasis with hypertension and obesity: a review. Am J Hypertens. 2008; 21: 257-264.
8. Coll DM, Varanelli MJ, Smith RC. Relationship of spontaneous passage of ureteral calculi to stone size and location as revealed by unenhanced helical CT. AJR Am J Roentgenol. 2002; 178: 101-103.
9. Stamatelon KK, Francis ME, Jones CA, Nyberg Jr LM, Curhan GC. Time trends in reported prevalence of kidney stones in the United States: 1976-1994. Kidney Int. 2003; 63:1817-1823.
10. Lieske JC, Pena de la Vega LS, Slezak JM, Bergstralh EJ, Leibson CL, K-L Ho. Renal stone epidemiology in Rochester, Minnesota: An update. Kidney Int. 2006; 69:760-764.
11. Colobawalla BN. Incidence of urolithiasis in India. ICMR Tech Rep Series No 8. 1971; 42-51.
12. Pendse AK, Singh PP. The etiology of urolithiasis in Udaipur (western part of India). Urol Res. 1986; 14:59-62
13. Bakane BC, Nagtilak SB, Patil B. Urolithiasis in Satpura region: A Tribal Experience. International Med J.1996; 3: 215-17.
14. Pendse AK. Urolithiasis in Udaipur and Jodhpur: A comparative study on prevalence and urinary profile. Bull III, Ann Conf Urol Soc India1985; 12.
15. Coe FL, Parks JH, Asplin JR. The pathogenesis and treatment of kidney stones. N Engl J Med. 1992; 327: 1141-52
16. Ansari MS, Gupta NP, Hemal AK, Dogra PN, Seth A, Aron M. Spectrum of stone composition: structural analysis of 1050 upper urinary tract calculi from northern India. Int J Urol. 2005; 12(1):12-16.
17. Bakane BC, Nagtilak SB, Patil B. Urolithiasis: a Tribal Scenario. Indian J Pediatr. 1999; 66: 863-865.
18. Tiselius HG. Stone incidence and prevention. Brazilian Journal of Urology 2000; 26, 452-462.
19. Hussain M, Lal M, Ahmed S, Zafar N, Naqvi SA, Abid-ul-Hassan, Rizvi S. Management of urinary calculi associated with renal failure. Am. J. Urol. 1995; 45(8):205-208.
20. Johnson CM, Wilson DM, O’ Fallon WM. Renal stone epidemiology: A 25 year study in Rochester, Minnesota. Kidney Int.1979; 16: 624-631.
21. Robertson WG, Peacock M, Marshall DH. Prevalence of urinary stone disease in vegetarians. Eur Urol. 1982; 8:334–339.
22. Hiatt RA, Dales LG, Friedman GD, Hunkeler EM. Frequency of urolithiasis in a prepaid medical care program. Am J Epidemiol.1982; 115: 255-265.
23. Curhan GC Willett WC, Speizer FE. Comparison of dietary calcium with supplemental calcium and other nutrients as factors affecting the risk for kidney stones in women. Ann Inter Med. 1997; 126: 497.
24. Bergland KJ, Kinder JM, Asplin JR, Coe BJ, Coe FL. Influence of gender and age on calcium oxalate crystal growth inhibition by urine from relatives of stone forming patients. J Urol. 2002; 167: 2372-2376.
25. Barcelo P, Wuhl O, Servitge E, Rousaud A, Pak CY. Randomized double-blind study of potassium citrate in idiopathic hypocitraturic calcium nephrolithiasis. J Urol 1993; 150: 1761-1764.
26. Hamm LL, Hering-Smith KS. Pathophysiology of hypocitraturic nephrolithiasis. Endocrinol Metab Clin North Am. 2002 Dec; 31(4): 885-893
27. Pak CY, Fuller C, Sakhaee K, Preminger GM, Britton F. Long-term treatment of calcium nephrolithiasis with potassium citrate. J Urol 1985; 134: 11-19
28. Chatterjee A, Pakrashi SC. The Treatise on Indian Medicinal Plants, 2nd ed. New Delhi: National Institute of Science Communication and Information Resources. 2005, Vol 1.
29. Mukerji B. India’s wonder drug plant: Rauwolfia serpentina, birth of a new drug from an old Indian medicinal plant. In: Medal Lectures, Vol II. New Delhi: lndian National Science Academy, 1984, 973-982.
30. Khare CP. Indian Herbal Remedies: Rational Western Therapy, Ayurvedic, and Other Traditional Usage.
31. Narayana swami V, Ali VS. Pashanabheda. J. Res. Indian. Med. 1967; 1: 24.
32. Seshadri B. Advances in research in “Indian Medicine”, “Pashanbedi” drugs for urinary calculus. Udupa, K. N. (Eds), 1970, pp. 77-98.
33. Barry H. Antioxidant effects: A basis for drug selection. Drugs 1991; 42: 569-605.
34. Malini MM, Lenin M, Varalakshmi P. Protective effects of triterpenes on calcium oxalate crystal-induced peroxidative changes in experimental urolithiasis. Pharmacol Res. 2000; 41: 413-418.
35. Singh CM, Sachan SS. Management of urolithiasis by herbal drugs. J. Nepal. Pharm. Assoc. 1989; 7: 81-85.
36. Jehti RK, Duggal B, Sahota RS, Gupta M, Sofat JB. Important plants used in stone. India J Med Res. 1983; 78: 422-25.
37. Muthusamy VV, Muthu P. Usefulness of history- taking, Physical examination and diagonistic scoring in acute renal colic. Probe. 1980; 19: 130-131.
38. Chatterjee BN. Successful treatment of urinary tract infection and urinary calculi with Cystone. Probe. 1982; 22: 27-30
39. Yadav JK, Singhvi AN, Sharma N. Indigenous herbomineral drug calcuri. Med. Surg. 1981; 21: 15-18.
Published
Abstract Display: 296 
PDF Downloads: 509 
